Petersen S, Rayner M. Coronary heart disease statistics 2002 edition. British Heart Foundation Statistics Database Annual Compendium
Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004;18:139-185
Burn J,Dennis M, Bamford J, et al. Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1994;25:333-337
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993;153:598-615
Sega R, on behalf of the Eprosartan Study Group. Efficacy and safety of eprosartan in severe hypertension. Blood Pressure 1999;8:114-121
Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eposartan compared with nitrendipine for secondary prevention. Stroke 2005;36: (In Press). Additional information cited for the MOSES study was presented at the ESC, Munich, 2004/data on file
Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy 1999;19(4 Pt 2):102S-107Sv
Elliott WJ, for the Eprosartan Study Group. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J Hum Hypertens 1999;13:413-417
Oparil S. Eprosartan versus enalapril in hypertensive patients with angiotensin converting enzyme inhibitor-induced cough. Curr Ther Res 1999;60(1):1-14
Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55(5):244-251
Balt JC, Mathy MJ, Pfaffendorf M, et al. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001;19:2241-2250
McInnes G. Pocket reference to angiotensin II antagonists. Science Press 1998
Swales JD. Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood pressure Elevation: Regional and Global (EISBERG) project. J Hypertens 1999;17(suppl2):S15-S19
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572
ESH Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-1053
Brooks DP, Ruffolo RR. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J Hypertens 1999;17(Suppl 2):S27-S32
Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. Circulation 1997;96:308-315
Kannel W. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 2003;20:277-286
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264
Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764
London GM, Guerin A. Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. J Hypertens 1999;17(Suppl 2):S3-S6
Ziogas J, Cunnane TC. An electro-physiological study of the actions of angiotensin II at the sympathetic neuroeffector junction in the guinea pig vas deferens. Br J Pharmacol 1991;103:1196-1202
Tsuda K, Tsuda S, Ura M, et al. Inhibitory actions of captopril on norepinephrine release from adrenergic nerve endings in spontaneously hypertensive rats. Jpn Heart J 1988;29:475-483
Kannel WB. Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50
Messerli F. Antihypertensives and stroke reduction. In: Report from the satellite symposium held at XXVI Congress of the European Society of Cardiology, Munich, 30 August 2004
Medical Research Council Working Party. MRC trial of mild hypertension: principal results. BMJ 1985;291:97-104
MRC Working Party. Medical research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-413
The Dutch TIA trial study group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-548
Eriksson S, Olofsson B-O, Wester B-O, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995;5:21-25
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003
Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind trial. J Hypertens 2003;21:875-886
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031
Kulbertus H. Clinical study of the month. The CHARM study. Rev Med Liege 2003;58(10):646-652
Program for irbesartan mortality and morbidity evaluations (PRIME). Data on file.
Ram V. Eprosartan - a unique therapeutic profile. In: Report from the satellite symposium held at XXVI Congress of the European Society of Cardiology, Munich, 30 August 2004
Edwards RM, Aiyer N, Chilstein EH, et al. Pharmacological characterisation of the nonpeptide angiotensin II receptor antagonist SK&F 108566. J Pharmacol Exp Ther 1992;260:175-181
Hollenberg NK. Introduction. Pharmacotherapy 1999;19(4 Pt 2):71S-72S
Ilson B. Drug interaction studies with eprosartan, a novel angiotensin II receptor antagonist. Am J Hypertens 1998;11(4 Pt 2):108A (Abstract E051)
Christensen M, Ibsen H, Worck R. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypo-glycaemia. Clin Sci 2005;108:113-119
Ruilope L, Jager B, Prichard, B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Pressure 2001;10:223-229v
Punzi HA, Punzi CF, et al. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Human Hypertens 2004:1-7
Teitelbaum I, Chilvers M, Reiz RJS. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. Can J Cardiol 2004;20(Suppl C):11C-16C
Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. Am J Cardiol 2001;88:980-986
Franklin S, Khan S, Wong N, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999;100:354-360
de la Sierra A, Munoz A, Arcos E, et al. The effect of treatment with eprosartan on pulse pressure: factors predicting response. Can J Cardiol 2004;20(Suppl C):17C-22C
de la Sierra A, Munoz A, Arcos E, et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Pressure 2004;13(Suppl 2):5-10
Robles NR, Martin-Agueda B, Lopez-Munoz F, et al. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. Int J Clin Pract 2005;59(4):478-484
Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-1039
Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17(1):129-136
Gradman AH, Gray J, Maggiacomo F, et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Clin Ther 1999;21:442-453
Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999;15(1):9-14
Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999;15:25-32
Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr Med Res Opin 2001;17(1):8-17
Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002;16: 169-176
Lees KR, Bath PMW, Naylor AR. Secondary prevention of transient ischaemic attack and stroke. BMJ 2000;320:991-994
Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-1463
Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA 2002;288:1388-1395
Labios M, Martinez M, Gabriel F, et al. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens 2004;17(9):757-763
Makris TK, Stavroulakis G, Papadopoulos DP, et al. Eprosartan effect on fibrinolytic/haemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exptl Clin Res 2004;30(3):125-132
Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902-2907
Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 2004;15:524-537
Frank H, Schobel H-P, Vitkowsky J, et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 2003;63:617-623
Eprosartan Periodic Safety Update, Data on file, Solvay Pharmaceuticals
Eprosartan Summary of Product Characteristics (master)
Harland D, Duff D, Laing S, et al. Safety of eprosartan in elderly patients with hypertension. Am J Hypertens 1998; 11:78A (Abstract D039)
Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654
Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335
Burnier M, Hogman M, Nussberg J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 995;25:602-609
Böhm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Safety 2002;25(8):599-511
Tenero D, Martin D, Ilson B, et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos 1998;19: 351-356
Chapelsky MC, Martin DE, Tenero DM, et al. A dose proportionality study of eprosartan in healthy male volunteers. J Clin Pharmacol 1998;38:34-39
Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998;46:267-270
Tenero D, Martin D, Chapelsky M, et al. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy 1998;18(1):42-50
Martin DE, Chapelsky MC, Ilson B, et al. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998;38:129-137
Cox PJ, Bush BD, Gorycki PD, et al. The metabolic fate of eprosartan in healthy subjects. Exp Toxic Pathol 1996; 48(Suppl II):75-82
Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 1997;43:661-664
Kovacs S, Martin DE, Ilson B, et al. An evaluation of the pharmacokinetics of a single oral dose of eprosartan in hemodialysis-dependent patients with end stage renal disease compared to volunteers with normal renal function. Pharmacotherapy 1998;19:612-619